Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


SIRS-Lab and DxS enter into licensing agreement

Jena, Germany, Manchester, UK, September 22, 2008 - SIRS-Lab GmbH and DxS Ltd today announced that they entered into an EU-wide in-licensing agreement for the Scorpions® Technology including an option for worldwide IVD utilization. With the selection of the PCR platform technology, SIRS-Lab completes the technical design of its sepsis prediction and monitoring test SIQNATURETM. The first-in-class test is now accessible for selected scientific experts and will be fully available in 2009.

Further details and financial terms of the agreement were not disclosed.

“The careful review of technologies resulted in the selection of the best option to complete the SIQNATURETM product design. Now we expedite the commercialization of the novel test by clinical multicenter trials with leading international experts.” states SIRS-Lab’s CEO PD Dr. Stefan Russwurm. After the trial phase, SIQNATURETM will be broadly available for clinical routine as part of an integrated diagnostic product concept comprising pathogen detection and monitoring of the host response.

Commenting on the licence agreement, Dr Stephen Little, CEO of DxS, says: “We are very pleased to have signed this agreement with SIRS-Lab, and look forward to seeing Scorpions developed for use in sepsis prediction. It is a further confirmation of confidence in our powerful real-time PCR technology, the high sensitivity, speed and specificity of Scorpions means that it will be ideally suited for applications in the field of infectious diseases.'

Sepsis prediction and monitoring

In the field of infectious diseases, SIRS-Lab is first to succeed in identifying transcriptomic biomarkers which indicate sepsis earlier and more reliable than currently possible. Moreover the company successfully transferred those biomarkers into a rapid and easy to use probe based PCR test.

The molecular diagnostic test SIQNATURETM allows the early detection of sepsis by differentiating between infectious and non-infectious states in hospitalized patients. It further is a unique tool to monitor the progression of sepsis being the most frequent cause of death in surgical intensive care units. Currently, rapid diagnostics are an unmet medical need facing strong demand for improved diagnostic approaches.

- ends -

Notes to editors

About DxS Ltd

DxS is a personalised medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. Working in partnership with pharmaceutical companies to support the development and sales of targeted cancer therapies by providing biomarkers and companion diagnostics.

DxS has a continually expanding portfolio of cancer mutation products. The TheraScreen® range of CE-marked clinical diagnostic kits can identify genetic tumour mutations that affect how patients respond to cancer therapies, thus enabling doctors to provide the most beneficial treatment. DxS produce two clinical diagnostic kits, K-RAS and EGFR-29.

The TheraScreen: K-RAS Mutation kit is the only companion diagnostic for Vectibix® (Amgen Inc) and Erbitux® (Merck KgaA / Imclone Systems Inc / BMS) for the treatment of colorectal cancer. DxS has an exclusive global distribution agreement with Roche Diagnostics for the distribution of the TheraScreen: K-RAS and TheraScreen: EGFR29 Mutation kits.

DxS’ pioneering real-time PCR technology Scorpions® is highly regarded for its proven speed and sensitivity, and is combined with ARMS (allele specific PCR) to develop each unique DxS product. This class-leading technology is also available for licence to diagnostic companies, for research, or for other varied applications.

DxS is a private, venture capital-backed company operating from the heart of Manchester’s Technology Quarter in the UK.

For further information please visit

About SIRS-Lab GmbH
Located in Jena, Germany, SIRS-Lab is a molecular diagnostic company developing unique and innovative products to identify and monitor life-threatening infections as sepsis, one of the major causes of death in hospitals. Created as a spin-off of the University Klinik of Jena, SIRS-Lab was founded in 2000 by S. Russwurm, K. Reinhart, E. Straube, and H.-P. Saluz and currently employs 50 people.

For further information, please contact:

Sue Charles / Tony Stephenson /John Mc Intyre
College Hill Life Sciences
Tel: +44 (0)20 7866 7864

SIRS-Lab GmbH Jena
Press contact:
Axel Kunz
Tel: +49 (0) 3641 508 430

Publisher Contact Information:

DxS Ltd
+44 (0)20 7866 7864

Company profile of DxS Ltd (acquired by Qiagen)
Past press releases of DxS Ltd (acquired by Qiagen).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Feb 14€19.0MBiopharmaceuticals
Feb 14N/AInternet services
Feb 14€4.6MBusiness applications
Feb 13€13.0MBiopharmaceuticals
Feb 13€25.0MMedical devices
Feb 13€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.